IDH1/2 and FGFR mutations have been reported to occur at frequencies of 10–20% and 10–15% in ICC, respectively, and the corresponding targeted therapeutics, ivosidenib and pemigatinib, have been shown to be effective in clinical trials [36, 37]. This evidence concerns the gene IDH1 and intrahepatic cholangiocarcinoma.